The US Food and Drug has approved Imcivree (setmelanotide) for chronic weight management in adult and pediatric patients six years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing.
With this approval, US biotech Rhythm Pharmaceuticals’ (Nasdaq: RYTM) Imcivree becomes the first-ever FDA approved therapy for these rare genetic diseases of obesity. Rhythm’s shares leapt 25.6% to $30.35 by midday.
The company expects to make Imcivree commercially available in USA in first-quarter 2021. Rhythm’s marketing application for setmelanotide to treat people living with obesity is currently under European Medicines Agency review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze